TY - JOUR
T1 - Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
AU - Ragoonanan, Dristhi
AU - Khazal, Sajad J.
AU - Abdel-Azim, Hisham
AU - McCall, David
AU - Cuglievan, Branko
AU - Tambaro, Francesco Paolo
AU - Ahmad, Ali Haider
AU - Rowan, Courtney M.
AU - Gutierrez, Cristina
AU - Schadler, Keri
AU - Li, Shulin
AU - Di Nardo, Matteo
AU - Chi, Linda
AU - Gulbis, Alison M.
AU - Shoberu, Basirat
AU - Mireles, Maria E.
AU - McArthur, Jennifer
AU - Kapoor, Neena
AU - Miller, Jeffrey
AU - Fitzgerald, Julie C.
AU - Tewari, Priti
AU - Petropoulos, Demetrios
AU - Gill, Jonathan B.
AU - Duncan, Christine N.
AU - Lehmann, Leslie E.
AU - Hingorani, Sangeeta
AU - Angelo, Joseph R.
AU - Swinford, Rita D.
AU - Steiner, Marie E.
AU - Hernandez Tejada, Fiorela N.
AU - Martin, Paul L.
AU - Auletta, Jeffery
AU - Choi, Sung Won
AU - Bajwa, Rajinder
AU - Dailey Garnes, Natalie
AU - Kebriaei, Partow
AU - Rezvani, Katayoun
AU - Wierda, William G.
AU - Neelapu, Sattva S.
AU - Shpall, Elizabeth J.
AU - Corbacioglu, Selim
AU - Mahadeo, Kris M.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/7
Y1 - 2021/7
N2 - Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials.
AB - Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85101197431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101197431&partnerID=8YFLogxK
U2 - 10.1038/s41571-021-00474-4
DO - 10.1038/s41571-021-00474-4
M3 - Review article
C2 - 33608690
AN - SCOPUS:85101197431
SN - 1759-4774
VL - 18
SP - 435
EP - 453
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 7
ER -